Smith & Nephew plc
Health
Performance
4.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Smith & Nephew plc stock rating and score history

All changes in ratings, performance and outlook tracked over time.

10.01.2026
Risk creeping up. Stability not bulletproof anymore.
03.01.2026
On shaky ground. Struggling to find a clear direction.
07.11.2025
Losing steam. Not trending your way right now.
20.08.2025
Climbing out. Risks fading, but not out of the woods.

Smith & Nephew plc stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Smith & Nephew plc do? Business model and key facts

Get the full picture of Smith & Nephew plc: what it builds, where it operates, and how it makes money.

Smith & Nephew plc Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 17349

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

shop
Company facts
Deepak S. Nath
CEO
17349
Employees worldwide
shop
Performance
32.3%
Last 12 months
-23.39%
Last 5 years
shop
Growth
$5,81B
Revenue year
$412,00M
Net income
shop
Valuation
$14,38B
Market Cap
26.28
Price/Earnings Ratio

Stocks related to Smith & Nephew plc

Selected based on industry alignment and relative market positioning.

ZBH
Zimmer Biomet Holdings, Inc.
88.75
-0.55%
5.3
Sell
Buy
Zimmer Biomet Holdings, Inc.
PODD
Insulet Corporation
286.49
+1.27%
6.8
Sell
Buy
Insulet Corporation
STE
STERIS plc
268.26
+1.52%
2.1
Sell
Buy
STERIS plc
PEN
Penumbra, Inc.
350.49
+11.82%
3.6
Sell
Buy
Penumbra, Inc.
GMED
Globus Medical, Inc.
93.89
+1.55%
6.2
Sell
Buy
Globus Medical, Inc.

Smith & Nephew plc fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.